
Gene therapy valoctocogene roxaparvovec will not be up for re-evaluation by the US Food and Drug Administration (FDA) until September, biotech firm Biomarin has announced in a press release.
In the same statement, Biomarin also reports that no patient who received the highest drug dose has required the preventive hemophilia treatment known as prophylactic Factor VIII in the six years since they started the firm’s gene therapy.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app